Effect of cyclophosphamide, total body irradiation, and zidovudine on retrovirus proliferation and disease progression in murine AIDS

Immunomodulatory effect of gold sodium thiomalate on murine acquired immunodeficiency syndrome

Induction of IL-2 production and increased expression of CD25 were observed in C57BL/10 mice after weekly treatment with gold sodium thiomalate (GST). LP-BM5 murine leukemia virus (MuLV) infected mice treated with GST survived longer, had less cervical lymph node swelling, lower spleen weight, and fewer abnormalities in the expression of the cell surface markers, CD4, CD8a and CD45R/B220 on spleen cells than those that were not treated with GST. Thus, GST treatment may be beneficial through a decrease in disease progression via IL-2 induction in MuLV infected mice. This may have application in human immunodeficiency virus-infected individuals.

Treatment of HIV infection with cytoreductive agents

Advances in antiretroviral therapy have resulted in significant improvement in virological markers and clinical end points. However, studies have demonstrated that HIV can be recovered from patients in whom HIV RNA has been undetectable for prolonged periods of time, suggesting that the elimination half-life of latently infected cells may be longer than previously speculated. When used in the appropriate setting, cytoreductive agents may help expedite the elimination of the long-lived viral reservoir, and result in shorter administration of antiviral agents. In this article we discuss the potential use of cytoreductive agents as adjunctive therapy to antiretrovirals. In addition, we review those agents most likely to impact the viral reservoir and describe ongoing clinical trials designed to define the effect of cytoreductive therapy on those reservoirs. If a positive effect is demonstrated, these agents could ultimately be a powerful addition to the potent drugs currently being used to block HIV replication.

Establishment of a therapeutic model for retroviral infection using the genetic resistance mechanism of the host

Resistance to retroviral infection is often regulated by multiple genes that control different aspects of the host-virus interaction. Genetically distinct inbred strains of mice differ in their susceptibility to retrovirus and have allowed the identification of several host-resistant loci that regulate the host defense mechanism to retroviral infection. Using the murine retrovirus infection system, a therapeutic model has been developed of retrovirus infection in association with the resistant mechanism of host genes. The most effective result achieved with the model was when using bone marrow transplantation of retrovirus-resistant cells with receptor interference function, which was genetically defined by the Fv-4 resistant gene. The possible application of these findings to the gene therapy of retrovirus-induced disease of humans is discussed.

Immunosuppression by a noncytolytic virus via T cell mediated immunopathology. Implication for AIDS

HIV is basically a non- or poorly cytocidal virus. Therefore, HIV infections in humans represent an apparent perversity in the balance between the host immune system and infectious agent: This noncytopathic virus infects macrophages, antigen presenting cells, helper T cells and other host cells which are then destroyed by the CD8+ T cell immune response. Thus, HIV infects some of the key cells involved in immune reactions and therefore induces the immune system to destroy itself and thereby enables the virus to persist. Accordingly, immunosuppression is not a cause of HIV cytopathogenicity but a consequence of conventional T cell mediated immunopathology that destroys macrophages antigen presenting cells, T helper cells and facilitates infection by trivial intracellular parasites which eventually cause fatal disease. This immunopathological view of AIDS is testable and, if correct, impinges on rationales for AIDS prevention and treatment.